Mirza Mansoor Raza 4

What Happened Mirza Mansoor Raza, Chief Medical Officer of Acrivon Therapeutics (ACRV), was granted 174,068 derivative securities (reported as an acquisition, code A) on March 1, 2026. The reported price is $0.00, and the filing’s footnote describes these as shares subject to an option — i.e., an option award rather than an open‑market purchase or sale. No shares were sold and no cash was received.

Key Details

• Transaction date: 2026-03-01 (Form 4 filed 2026-03-03; filing appears timely).
• Transaction type/code: Grant/Award (A) of derivative securities (options).
• Amount: 174,068 shares; Price reported: $0.00.
• Vesting: 25% vests on March 1, 2027; remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to continuous service.
• Shares owned after transaction: Not specified in the filing.
• No indication of a 10b5-1 plan, cashless exercise, or sale in this filing.

Context This filing documents a compensation-related option grant that will vest over time. Because it is a grant (not a purchase or immediate sale), it does not represent an immediate cash outlay or market sale by the insider and should be viewed primarily as part of executive compensation rather than a direct bullish/bearish trading signal.